Market's view on Creo Medical

Published on April 2024

  • Stock watchers are debating the company’s financial stability, with some expecting another cash placement soon due to perceived insufficient funds to reach break-even. Others argue the company has adequate cash reserves to reach profitability without additional funding.
  • There are positive expectations on the company’s stock as Cavendish/Numis issued price targets around 99-100p, but stock watchers remain cautious due to potential biases from house brokers.
  • Discussions highlight the company’s progress in obtaining multiple international patents, deemed a positive development indicating functional operations.
  • The implementation of lung ablation and its clinical benefits are seen as potentially transformative for the company, with minimal downsides apart from initial costs.
  • The company is reported to have good traction in sales and business progression, with a notable increase in sales of core products.
  • Concerns are raised about the company’s cash flow management and the need for a robust plan to ensure financial stability.
  • The recent positive health economics report for the SSD use case by RWE has been well received, though its impact on NHS procurement processes remains uncertain.
  • There are predictions about the company possibly preparing for an exit strategy in the future, as inferred from the CEO’s background and company activities.
  • Expectations are set for the company to continue gaining ground, especially with potential collaborations like those with Intuitive’s da Vinci systems, which could significantly enhance market opportunities.
  • Upcoming financial results and updates on executive appointments are highly anticipated, seen as potential catalysts for future company performance.
← Back to Home